PEGPH20 May Improve Standard-of-Care Therapy in Pancreatic Cancer [Research Watch]

The HA-degrading drug PEGPH20 plus standard therapy extends survival in metastatic pancreatic cancer.

from Cancer via ola Kala on Inoreader http://ift.tt/2BYl0Ce
via IFTTT